Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cance...(eloma cell lines and preferentiallyinduc...),Health

Date:4/16/2008

eloma cell lines and preferentially induced apoptosis in primary multiple myeloma cells versus peripheral blood mononuclear cells. In a series of studies examining SNS-032's mechanism of action and activity in human myeloma cell lines, SNS-032 inhibited proliferation and induced apoptosis, down-regulating key anti-apoptotic proteins and resulting in G1 arrest. In addition, SNS-032 was active in combination with two approved agents for multiple myeloma, bortezomib (Velcade(R)) and lenalidomide (Revlimid(R)), in human myeloma cell lines. SNS-032 also demonstrated anticancer activity in vivo in a transgenic mouse model of multiple myeloma. These data (Abstract #4972) were presented during a minisymposium on Novel Genomic Approaches, Drugs, Targets, and Strategies in a talk titled "SNS-032, a potent and selective CDK2, 7 and 9 inhibitor, demonstrates preclinical activity in human multiple myeloma."

In addition, on Sunday, April 13, 2008 at the AACR Annual Meeting, William Plunkett, Ph.D., Professor and Chief, Section of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, presented translational research data detailing the relationship between SNS-032's mechanism and its activity in mantle cell lymphoma. Mantle cell lymphoma is an aggressive form of Non-Hodgkin's lymphoma driven by the over-expression of certain oncoproteins, including cyclin D1, Mcl-1 and Myc. SNS-032's targeted inhibition of CDKs 7 and 9 blocks transcription of these proteins, resulting in cell death in a panel of mantle cell lymphoma cell lines. These data were presented at the AACR Annual Meeting in a poster titled "SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7, and 9, blocks transcription of cyclin D1 and Mcl-1, causing cell death in mantle cell lymphoma cell lines" (Abstract #756).

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of nove
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
2. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
6. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
7. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
8. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
11. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia